Different effects of ionotropic and metabotropic glutamate receptor antagonists on attention and the attentional properties of nicotine

Neuropharmacology

Volumn 53, Issue 3, 2007, Pages 421-430

  Quarta, Davide ^a   Naylor, Christopher G ^a   Morris, Hannah V ^a   Patel, Swital ^a   Genn, Rachel F ^a   Stolerman, Ian P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Attention; Behaviour; CPP; Glutamate; mGlu5; MPEP; Nicotine; NMDA

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINE TARTRATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTICIPATION; ARTICLE; ATTENTION; BEHAVIOR; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; INSTRUMENTAL CONDITIONING; LATENT PERIOD; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; RESPONSE TIME; SINGLE DRUG DOSE; TASK PERFORMANCE;

ANALYSIS OF VARIANCE; ANIMALS; ATTENTION; BEHAVIOR, ANIMAL; CHOICE BEHAVIOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; NICOTINE; NICOTINIC AGONISTS; PIPERAZINES; PYRIDINES; RATS; REACTION TIME; TASK PERFORMANCE AND ANALYSIS;

EID: 34547659043     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.05.023     Document Type: Article

References (56)

1. Alkondon M., and Albuquerque E.X. Nicotinic acetylcholine receptor α7 and α4α2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J. Neurophysiol. 86 (2001) 3043-3055
2. Balschun D., and Wetzel W. Inhibition of mGluR5 blocks hippocampal LTP in vivo and spatial learning in rats. Pharmacol. Biochem. Behav. 73 (2002) 375-380
3. Bespalov A.Y., Dravolina O.A., Sukhanov I., Zakharova E., Blokhina E., Zvartau E., Danysz W., van Heeke G., and Markou A. Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology 49 Suppl. 1 (2005) 167-178
4. Bizarro L., Patel S., and Stolerman I.P. Comprehensive deficits in performance of an attentional task produced by co-administering alcohol and nicotine to rats. Drug Alcohol Depend. 72 (2003) 287-295
5. Briggs C.A., and McKenna D.G. Effect of MK-801 at the human alpha 7 nicotinic acetylcholine receptor. Neuropharmacology 35 (1996) 407-414
6. Buisson B., and Bertrand D. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53 (1998) 555-563
7. Chaudhri N., Caggiula A.R., Donny E.C., Booth S., Gharib M., Craven L., Palmatier M.I., Liu X., and Sved A.F. Operant responding for conditioned and unconditioned reinforcers in rats is differentially enhanced by the primary reinforcing and reinforcement-enhancing effects of nicotine. Psychopharmacology 189 (2006) 27-36
8. 3H]-dopamine release. Br. J. Pharmacol. 117 (1996) 595-606
9. Dalley J.W., Theobald D.E., Berry D., Milstein J.A., Laane K., Everitt B.J., and Robbins T.W. Cognitive sequelae of intravenous amphetamine self-administration in rats: evidence for selective effects on attentional performance. Neuropsychopharmacology 30 (2005) 525-537
10. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 65 (2001) 1-105
11. Everitt B.J., and Robbins T.W. Central cholinergic systems and cognition. Annu. Rev. Psychol. 48 (1997) 649-684
12. Farber N.B., Newcomer J.W., and Olney J.W. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog. Brain Res. 116 (1998) 421-437
13. Franken I.H. Drug craving and addiction: integrating psychological and neuro-psychopharmacological approaches. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 563-579
14. Fu Y., Matta S.G., Gao W., Brower V.G., and Sharp B.M. Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-d-aspartate receptors in the ventral tegmental area. J. Pharmacol. Exp. Ther. 294 (2000) 458-465
15. Fu Y., Matta S.G., Gao W., and Sharp B.M. Local alpha-bungarotoxin-sensitive nicotinic receptors in the nucleus accumbens modulate nicotine-stimulated dopamine secretion in vivo. Neuroscience 101 (2000) 369-375
16. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., and Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38 (1999) 1493-1503
17. Gioanni Y., Rougeot C., Clarke P.B., Lepouse C., Thierry A.M., and Vidal C. Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur. J. Neurosci. 11 (1999) 18-30
18. Glick S.D., Maisonneuve I.M., Dickinson H.A., and Kitchen B.A. Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats. Eur. J. Pharmacol. 422 (2001) 87-90
19. Hahn B., and Stolerman I.P. Modulation of nicotine-induced attentional enhancement in rats by adrenoceptor antagonists. Psychopharmacology 177 (2005) 438-447
20. Hahn B., Shoaib M., and Stolerman I.P. Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task-demands. Psychopharmacology 162 (2002) 129-137
21. Hahn B., Shoaib M., and Stolerman I.P. Effects of dopamine receptor antagonists on nicotine-induced attentional enhancement. Behav. Pharmacol. 13 (2002) 621-632
22. Hahn B., Sharples C.G., Wonnacott S., Shoaib M., and Stolerman I.P. Attentional effects of nicotinic agonists in rats. Neuropharmacology 44 (2003) 1054-1067
23. Harrison A.A., Gasparini F., and Markou A. Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology 160 (2002) 56-66
24. Higgins G.A., Ballard T.M., Huwyler J., Kemp J.A., and Gill R. Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology 44 (2003) 324-341
25. Higgins G.A., Enderlin M., Haman M., and Fletcher P.J. The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. Psychopharmacology 170 (2003) 309-319
26. Homayoun H., and Moghaddam B. Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb. Cortex 16 (2006) 93-105
27. Jones S., and Yakel J.L. Functional nicotinic ACh receptors on interneurones in the rat hippocampus. J. Physiol. 504 (1997) 603-610
28. Kenny P.J., and Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol. Sci. 25 (2004) 265-272
29. Kinney G.G., Burno M., Campbell U.C., Hernandez L.M., Rodriguez D., Bristow L.J., and Conn P.J. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 306 (2003) 116-123
30. Koelega H.S. Stimulant drugs and vigilance performance: a review. Psychopharmacology 111 (1993) 1-16
31. Konradi C., and Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol. Ther. 97 (2003) 153-179
32. Levin E.D., and Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138 (1998) 217-230
33. Levin E.D., McClernon F.J., and Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 184 (2006) 523-539
34. Lu Y.M., Jia Z., Janus C., Henderson J.T., Gerlai R., Wojtowicz J.M., and Roder J.C. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17 (1997) 5196-5205
35. Mansvelder H.D., van Aerde K.I., Couey J.J., and Brussaard A.B. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology 184 (2006) 292-305
36. Meldrum B., and Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11 (1990) 379-387
37. 2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 29 (2004) 1637-1647
38. Mirza N.R., and Stolerman I.P. Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology 138 (1998) 266-274
39. Murphy E.R., Dalley J.W., and Robbins T.W. Local glutamate receptor antagonism in the rat prefrontal cortex disrupts response inhibition in a visuospatial attentional task. Psychopharmacology 179 (2005) 99-107
40. Paterson N.E., and Markou A. The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology 179 (2005) 255-261
41. Raiteri M., Garrone B., and Pittaluga A. N-methyl-D-aspartic acid (NMDA) and non-NMDA receptors regulating hippocampal norepinephrine release. II. Evidence for functional cooperation and for coexistence on the same axon terminal. J. Pharmacol. Exp. Ther. 260 (1992) 238-242
42. Rezvani A.H., and Levin E.D. Nicotinic-glutamatergic interactions and attentional performance on an operant visual signal detection task in female rats. Eur. J. Pharmacol. 465 (2003) 83-90
43. Rezvani A.H., Caldwell D.P., and Levin E.D. Nicotinic-serotonergic drug interactions and attentional performance in rats. Psychopharmacology 179 (2005) 521-528
44. Rezvani A.H., Kholdebarin E., Dawson E., and Levin E.D. Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. Int. J. Neuropsychopharmacol. (2007) 10.1017/S1461145706007528
45. Risso F., Grilli M., Parodi M., Bado M., Raiteri M., and Marchi M. Nicotine exerts a permissive role on NMDA receptor function in hippocampal noradrenergic terminals. Neuropharmacology 47 (2004) 65-71
46. Robbins T.W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 163 (2002) 362-380
47. Rosenmund C., Stern-Bach Y., and Stevens C.F. The tetrameric structure of a glutamate receptor channel. Science 280 (1998) 1596-1599
48. Sarter M. Preclinical research into cognition enhancers. Trends Pharmacol. Sci. 27 (2006) 602-608
49. Schoepp D.D., Jane D.E., and Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38 (1999) 1431-1476
50. Semenova S., and Markou A. The effects of the mGluR5 antagonist MPEP and the mGluR2/3 antagonist LY341495 on rats' performance in the 5-choice serial reaction time task. Neuropharmacology 52 (2007) 863-872
51. Shoaib M., and Bizarro L. Deficits in a sustained attention task following nicotine withdrawal in rats. Psychopharmacology 178 (2005) 211-222
52. Shoaib M., Benwell M.E., Akbar M.T., Stolerman I.P., and Balfour D.J. Behavioural and neurochemical adaptations to nicotine in rats: influence of NMDA antagonists. Br. J. Pharmacol. 111 (1994) 1073-1080
53. Tessari M., Pilla M., Andreoli M., Hutcheson D.M., and Heidbreder C.A. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur. J. Pharmacol. 499 (2004) 121-133
54. Vidal C., and Changeux J.P. Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro. Neuroscience 56 (1993) 23-32
55. Wang F., Chen H., Steketee J.D., and Sharp B.M. Upregulation of ionotropic glutamate receptor subunits within specific mesocorticolimbic regions during chronic nicotine self-administration. Neuropsychopharmacology 32 (2006) 103-109
56. Willetts J., Bobelis D.J., and Balster R.L. Drug discrimination based on the competitive N-methyl-D- aspartate antagonist, NPC 12626. Psychopharmacology 99 (1989) 458-462